Capecitabine Versus S-1 in Elderly Advanced Gastric Cancer (AGC): Randomized Trial
Status:
Completed
Trial end date:
2007-01-01
Target enrollment:
Participant gender:
Summary
A significant proportion of advanced gastric cancer (AGC) occurs in individuals 65 years of
age and older. In addition, patient delay in seeking care for symptoms results in diagnosis
at a more advanced stage than that seen in younger individuals. However, clinical trials on
gastric cancer rarely have been available to the elderly. Recently oral 5-FU pro-drugs, which
have been reported to have clinically significant response rates and survival with mild or
negligible toxicities, have been widely used for the patients with AGC. However, few studies
have been conducted in elderly patients.